Drug Trial Radar · NCT06937177
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Endevica BioIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) or 2) patients with newly diagnosed, advanced, unresectable pancreatic ductal adenocarcinoma (PDAC). Within each cohort, patients will be randomized 1:1:1:1 to receive placebo or one of three different doses of mifomelatide (12.5 mg, 25 mg, or 50 mg). This study is designed to evaluate the effects of different doses of mifomelatide on weight, body composition and BMI. The double-blind (DB) phase will generally begin on the first day of the second cycle of first-line cancer chemotherapy and continue for 12-weeks with the goal of maintaining body weight and muscle mass in patients undergoing chemotherapy relative to control. Upon completion of the DB treatment period, eligible patients may enroll in an optional Open Label Extension (OLE) phase and receive mifomelatide SC 25 mg daily for up to an additional 26 weeks. The purpose of the OLE is to further evaluate long-term safety, tolerability and efficacy of mifomelatide.
Conditions
- Cancer Weight Loss
Interventions
TCMCB07Drug
TCMCB07 is will be provided in single-use vials for subcutaneous administration
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in body weightTime frame: At 12 weeks of treatment
- Incidence and severity of adverse events (AEs), AESIs, and SAEsTime frame: From enrollment to the end of the 12 week dosing period
- Incidence of abnormalities in laboratory evaluationsTime frame: From enrollment to the end of the 12 week dosing period
- Incidence of abnormalities in vital signsTime frame: From enrollment to the end of the 12 week dosing period
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Clinical Research Center
Tucson, Arizona · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UCLA Medical Center
Santa Monica, California · Recruiting
Life Clinical Trials
Coral Springs, Florida · Recruiting
Bioresearch Partners
Hialeah, Florida · Recruiting
D&H Cancer Research Center
Margate, Florida · Recruiting
Mt. Sinai Cancer Center
Miami Beach, Florida · Recruiting
BRCR Global
Tamarac, Florida · Recruiting
Piedmont Healthcare Inc.
Atlanta, Georgia · Recruiting
Northwestern University - Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois · Not yet recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Not yet recruiting
Orchard Healthcare Research
Skokie, Illinois · Recruiting
Cancer Centers of Kansas
Wichita, Kansas · Recruiting
Karmanos Cancer Center
Detroit, Michigan · Recruiting
NHO Revive Research Institute
Lincoln, Nebraska · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
NYU Langone Health Perlmutter Cancer Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Hightower Clinical
Oklahoma City, Oklahoma · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Not yet recruiting
Baptist Clinical Research
Memphis, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Not yet recruiting
Lumi Research
Kingwood, Texas · Recruiting
Laguna Clinical Research Associates
Laredo, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.